DENVER & MONTREAL--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (“Ceragenix”) (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology today announced that it has entered into an exclusive distribution and supply agreement (the “Agreement”) with Pediapharm Inc. (“Pediapharm”), to commercialize EpiCeram®, a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in Canada (the “Territory”). The Agreement grants Pediapharm exclusivity in the Territory for the distribution and marketing of EpiCeram® while Ceragenix will be responsible for the manufacturing and supply of the product. Pediapharm is also responsible for obtaining regulatory clearance to market EpiCeram® in the Territory. Financial terms were not disclosed.
